Nonobese diabetic (NOD) mice develop diabetes and destroy syngeneic islet grafts through an autoimmune response. Because transforming growth factor (TGF)-β1 downregulates immune responses, we tested whether overexpression of TGF-β1 by gene transfection of NOD mouse islets could protect β-cells in islet grafts from autoimmune destruction. NOD mouse islet cells were transfected with an adenoviral DNA expression vector encoding porcine latent TGF-β1 (Ad TGF-β1) or the adenoviral vector alone (control Ad vector). The frequency of total islet cells expressing TGF-β1 protein was increased from 12 ± 1% in control Ad vector-transfected cells to 89 ± 4% in Ad TGF-β1-transfected islet cells, and the frequency of β-cells that expressed TGF-β1 was increased from 12 ± 1% to 60 ± 7%. Also, secretion of TGF-β1 was significantly increased in islets that overexpressed TGF-β1. Ad TGF-β1-transfected NOD mouse islets that overexpressed TGF-β1 prevented diabetes recurrence after transplantation into diabetic NOD mice for a median of 22 days compared with only 7 days for control Ad vector-transfected islets (p = 0.001). Immunohistochemical examination of the islet grafts revealed significantly more TGF-β1 + cells and insulin + cells and significantly fewer CD45 + leukocytes in Ad TGF-β1-transfected islet grafts. Also, islet β-cell apoptosis was significantly decreased whereas apoptosis of graft-infiltrating leukocytes was significantly increased in Ad TGF-β1-transfected islet grafts. These observations demonstrate that overexpression of TGF-β1, by gene transfection of NOD mouse islets, protects islet β-cells from apoptosis and autoimmune destruction and delays diabetes recurrence after islet transplantation. 519 520 SUAREZ-PINZON ET AL.
INTRODUCTION
fication of the graft to secrete immunosuppressive factors belongs to the latter approach. Type I diabetes mellitus is an autoimmune disease Genetic modifications of islets preceding transplantamediated by autoreactive T cells that infiltrate and cause tion have been reported to prolong islet graft survival by destruction of the insulin-producing β-cells in the pansite-specific delivery of immunosuppressive molecules creatic islets of Langerhans. Similarly, β-cells in whole (8, 11) . Islet allografts biolistically transfected with pancreas or islet transplants are destroyed by a recurrent DNA expression vectors encoding CTLA4Ig to block autoimmune response in human subjects with type I dia-T cell co-stimulation, or soluble Fas ligand to delete Fas betes (13, 29) . Systemic immunosuppressive drug therareceptor-bearing activated T cells, were partially propies have recently improved survival in patients with tected from rejection after transplantation into alloxanautoimmune, type I diabetes (25, 26) ; however, toxicity diabetic mice (5) . In another study, lentivirus-mediated and infections accompany systemic immunosuppression transfection of syngeneic islet grafts with the immunoand therefore other approaches are being explored. One suppressive cytokine, interleukin (IL)-4, protected approach is to induce immunological tolerance to the against autoimmune insulitis and β-cell destruction in islet transplant and thereby eliminate the need for con-NOD mice (6) . Also, adenoviral-mediated transfection tinued systemic immunotherapy. Another approach is to of syngeneic islet grafts with the p40 subunit of IL-12, induce a local inhibition or blockade of pathogenic iman antagonist of the proinflammatory cytokine IL-12, mune responses directed against the graft. Genetic modiprotected islet grafts from autoimmune destruction in diabetic NOD mice (32). In a preliminary report, trans-supplemented with 2% heat-inactivated fetal calf serum. The cells were either not transfected or transfected by plantation of islets transfected with adenoviral vectors encoding the immunosuppressive cytokines, IL-10 and incubation with a recombinant adenovirus DNA expression vector containing the cDNA of the coding region transforming growth factor (TGF)-β1, significantly prolonged survival of discordant (dog-to-rat) xenogeneic is-of full-length porcine latent (inactive) TGF-β1 (Ad TGF-β1) or control adenovirus, DL 70-3 (control Ad let grafts (4) .
In view of the importance of TGF-β1 in immunoreg-vector). Ad TGF-β1 and Ad control vectors were constructed and kindly provided by Dr. Jack Gauldie, ulation and tolerance, and reports that increased TGF-β1 production correlates with protection and/or recovery McMaster University, Hamilton, Ontario (27) . Islet cells were transfected at a multiplicity of infection (MOI) from autoimmune diseases (23), we sought to determine if local overexpression of TGF-β1 could protect β-cells from 0.5:1 to 100:1. A MOI of 20:1 (1 × 10 7 viral plaque forming units added per 5 × 10 5 islet cells) was used to in islet grafts from autoimmune destruction after transplantation into diabetic NOD mice. In the present study, transfect islet cells for assessment of TGF-β1 expression and secretion and for islet transplantations, because we transfected NOD mouse islets with the latent form of TGF-β1 normally secreted by cells, and we found that higher MOI (≥50:1) impaired islet cell viability and glucose-induced insulin release. After 6-8-h incubation at the islet β-cells expressed and secreted latent TGF-β1 and were protected from autoimmune destruction after 37°C with 5% CO 2 , without and with Ad TGF-β1 or control vectors, the islet cells were collected and washed transplantation into diabetic NOD mice.
in Opti-MEM I medium supplemented either with 2%
MATERIALS AND METHODS
heat-inactivated fetal calf serum for study of TGF-β1 Animals secretion in vitro, or with 5% heat-inactivated NOD mouse serum for islet cell transplantation studies. NOD female mice were purchased from Taconic (Germantown, NY) and were maintained and fed under Immunohistochemical Characterization specific pathogen-free conditions. Diabetes onset in feof Transfected Islet Cells male NOD mice was at age 10-12 weeks and diabetic TGF-β1 expression by the Ad TGF-β1 and control incidence increased to 80-100% by age 30 weeks. Dia-Ad vector-transfected and nontransfected islet cells was betic mice were treated by daily SC injections of a 1:1 determined by immunohistochemical staining of both tomix of regular pork and beef insulin (1.0 U/100 g body tal islet cells and islet β-cells, as previously described weight) (Eli Lilly, Indianapolis, IN) for 3-6 weeks be- (24) . Briefly, islet cells (50 × 10 3 ) were placed on glass fore receiving transplants of syngeneic islets isolated slides coated with 3-aminopropyltriethoxysilane, fixed from 4-week-old female NOD mice. All mice were in 4% paraformaldehyde, then permeabilized with 1.5% cared for according to the guidelines of the Canadian saponin in PBS. Islet β-cells were stained by incubation Council on Animal Care. with a guinea pig anti-insulin antibody (Linco Research,
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St. Louis, MO) or guinea pig control antibody, followed by a biotinylated goat anti-guinea pig antibody, then a Islets isolated from 4-week-old female NOD mice were batched in groups of 500 islets and maintained steptavidin-alkaline phosphatase conjugate and a 4chloro, 1 naphthol chromogen, which stained insulin-overnight at 37°C with 5% CO 2 in 15 × 100-mm petri dishes containing RPMI-1640 medium with 11 mmol/L containing cells (β-cells) blue. TGF-β1 protein-expressing islet cells were stained by incubation with a rabbit glucose, 2 mmol/L L-glutamine, 0.1 mmol/L sodium pyruvate, 10% heat-inactivated fetal calf serum, 100 U/ml antibody specific for TGF-β1 (ac-146, Santa Cruz Biotechnology, Santa Cruz, CA) or rabbit control antibody, penicillin, 100 µg/ml streptomycin, 0.25 µg/ml amphotericin B, and 12 mmol/L HEPES (Life Technologies, followed by biotinylated goat anti-rabbit antibody, then a streptavidin-peroxidase conjugate and peroxidase Fast-Burlington, Ontario) (complete medium). Each batch of 500 islets was then dissociated into smaller aggregates red chromogen, which stained TGF-β1-containing cells red. To colocalize TGF-β1 to β-cells, cells were stained of approximately 10 cells or less, by incubation at 25°C for 10 min in Ca 2+ /Mg 2+ -free phosphate-buffered saline for insulin as described above, then left in PBS overnight at 4°C to remove nonspecific binding, and stained (PBS) containing 0.2 mg/ml EDTA (Life Technologies) followed by gentle syringe injection through progres-for TGF-β1 as described above. β-Cells expressing TGF-β1 were identified by a dark blue granular staining sively narrower gauge needles from size 14 to 22. The islet cells were then incubated overnight at 37°C with (insulin + ) on a more diffuse bright red cytoplasmic staining (TGF-β1 + ). Slides were sealed for microscopic ex-5% CO 2 in 15 × 100-mm petri dishes containing complete medium. Next, the islet cells were washed and re-amination. Cell preparations were stained in duplicate with each test or control primary antibody and 3000 suspended in Opti-MEM I medium (Life Technologies) TGF-β1 EXPRESSION PROTECTS ISLET GRAFTS FROM AUTOIMMUNE DESTRUCTION 521 cells were scored blindly by two independent observers, Mg 2+ -free PBS with 0.2 mg/ml EDTA (Life Technologies). TGF-β1 + cells and insulin + cells were identified by who each scanned approximately 50 different microscopic fields.
immunohistochemistry as described (see Immunohistochemical Characterization of Transfected Islet Cells).
TGF-β1 Secretion by Transfected Islet Cells
Leukocytes were identified by staining paraformalde-Ad TGF-β1 and Ad control vector-transfected islet hyde-fixed cells with a rat monoclonal antibody (Ly-5/ cells from 500 islets were incubated for 48 h at 37°C in T-200) to total leukocytes (CD45 + cells) (Cedarlane, 1.0 ml complete medium. TGF-β1 in islet cell incuba-Hornby, Ontario) or rat IgG control antibody, followed tion media was measured by ELISA as previously reby biotinylated goat anti-rat mouse-absorbed IgG, then ported (7) . Active TGF-β1 was measured in nonacidisteptavidin-alkaline phosphatase conjugate and alkaline fied media samples; also, the samples were acidified phosphatase Fast-blue. β-cells (insulin + ) and leukocytes before ELISA (converts latent to active TGF-β1) to (CD45 + ) undergoing apoptosis were identified by stainmeasure total (latent and active) TGF-β1. Latent TGFing first for the respective cell types as described above, β1 was calculated as the difference between total TGFfollowed by detection of DNA strand breaks (nicks) in β1 and active TGF-β1.
these cells by the TdT-mediated dUTP nick end labeling (TUNEL) method using a cell death detection kit (Roche
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Diagnostics, Laval, Quebec). A TUNEL-peroxidase con-Pancreases from 16-20 4-week-old female NOD jugated detection antibody (Roche) was added to the mice were pooled for each islet isolation procedure. Isinsulin + and CD45 + -stained cells for 2 h at room temperlets were isolated by collagenase digestion of the panature, followed by washing in PBS with 1.5% saponin creas and Ficoll density gradient purification, and then (PBS-saponin) for 30 min. Peroxidase converter reagent hand picked (12) . Batches of 500 islets (from approxiwas added for 20 min at 37°C, then the cells were mately four donor mice) were dissociated into smaller washed in PBS-saponin, and an aminoethylcarbazole cell aggregates and either not transfected or transfected chromogen was added. Cells with DNA strand breaks with Ad TGF-β1 or control Ad vector, as described (see (apoptotic cells) were identified by red nuclear staining. Islet Transfections). The islet cell aggregates were then Apoptotic β-cells (TUNEL + insulin + ) and apoptotic leutransplanted under the left renal capsule of a diabetic kocytes (TUNEL + CD45 + ) were stained red in the nu-NOD mouse, according to a previously described procecleus and blue in the cytoplasm (β-cells) or cell surface dure (31) . Transplantation was considered successful if (leukocytes). the nonfasting blood glucose returned to normal (<7 Statistical Analyses mmol/L) and remained normal for the first 4 days after Islet graft survival times (median days after transtransplantation. Urine was monitored daily after transplantation) were compared for significant differences by plantation, using Keto-Diastix (Bayer, Etobicoke, Onthe Mann-Whitney rank sum test. All other data are tario) and if glucosuria (>6 mmol/L) and ketonuria (>1. 5 expressed as mean ± SE values. Differences between mmol/L) appeared, then tail vein blood glucose was groups were analyzed by ANOVA with Tukey-Kramer's measured in a glucose meter (Glucometer Elite, Bayer). multiple comparisons test; p < 0.05 was considered sig-Islet graft rejection was diagnosed by return of hypernificant. glycemia (blood glucose >12 mmol/L). In the first study, the mice were monitored for duration of islet graft sur-RESULTS vival (maintenance of normoglycemia). In the second Expression and Secretion of TGF-β1 study, islet grafts were removed at 8-12 days after in Transfected Islets transplantation and examined histologically and by immunohistochemistry.
Transfection of NOD mouse islet cells with Ad TGF-β1 increased the frequency of islet cells that expressed Histological Studies TGF-β1 protein sevenfold, and the frequency of islet Grafts were fixed in 10% buffered formalin, embedcells that expressed both TGF-β1 and insulin was inded in paraffin, sectioned at 4.5 µm, then stained with creased fivefold; also, the percentage of β-cells that exeosin and counterstained with hematoxylin.
pressed TGF-β1 was increased fivefold from 12 ± 1% to 60 ± 7% (Fig. 1 ). In addition, NOD mouse islets cells Immunohistochemical Studies of Islet Grafts transfected with Ad TGF-β1 secreted significantly more TGF-β1 than islet cells transfected with control Ad vec-The islet grafts were cut into small pieces with fine scissors, disrupted by syringe injections through pro-tor. Ad TGF-β1-transfected islet cells secreted 85 ± 6 ng latent TGF-β1 protein/500 islets/48 h compared with 12 gressively narrower gauge needles from size 14 to 22, and dissociated into single cells by incubation in Ca 2+ / ± 1 ng secreted by control Ad vector-transfected islet cells (Fig. 2) . Only small amounts of the active form of days after islet transplantation and before diabetes recurrence. TGF-β1-expressing cells and β-cells were signifi-TGF-β1 were secreted by either Ad TGF-β1-transfected or control Ad vector-transfected islet cells as expected cantly greater in islet grafts transfected with Ad TGF-β1 than with control Ad vector, whereas islet graft-infil-because cells normally secrete the latent and not the active form of TGF-β1, and we transfected the islet cells trating leukocytes were significantly less in Ad TGF-β1transfected islet grafts (Fig. 6 ). Also, apoptotic β-cells with a vector encoding the latent form of TGF-β1.
were significantly decreased whereas apoptotic leuko-
Effects of TGF-β1 Overexpression by Islet Grafts
cytes were significantly increased in islet grafts transfecin NOD Mice ted with Ad TGF-β1 ( Fig. 7) . Therefore, TGF-β1 over-Islet transplantations corrected hyperglycemia in diaexpression in islet grafts resulted in increased apoptosis betic NOD mice within 1-2 days; however, diabetes reand reduction of graft-infiltrating leukocytes, together curred (blood glucose >12 mmol/L) from day 6 to 11 in with decreased apoptosis and increased survival of βmice with nontransfected islet grafts, and from day 6 to cells in the islet grafts. 14 in mice with control Ad vector-transfected islet DISCUSSION grafts. In contrast, diabetes did not recur in mice with Type I diabetes, like other organ-specific auto-Ad TGF-β1-transfected islet grafts until days [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] immune diseases, results from a disorder of immuno- (Fig. 3) , and median graft survival was prolonged to 22 regulation in which one or another immunoregulatory days in mice with Ad TGF-β1-transfected islet grafts mechanism (e.g., regulatory T cells) fails, allowing autcompared with only 7 days in mice with control Ad vecoreactive T cells to expand clonally and destroy islet tor-transfected islet grafts (Fig. 4) . Leukocytic infiltraβ-cells. Cytokines are important immunoregulatory moltion was extensive and little islet tissue remained in ecules and cytokine therapy can influence the outcome grafts transfected with control Ad vector whereas fewer of autoimmune diseases (17, 28) . In this study, we foleukocytes and more islet cells were present in Ad TGFcused on the potential immunosuppressive role of TGF-β1-transfected islet grafts at 10 days after islet transplan-β1 in autoimmune murine diabetes. TGF-β1 is a multitation ( Fig. 5 ).
functional cytokine with numerous anti-inflammatory Immunohistochemical Analysis of Islet Grafts effects (16,23). Importantly, TGF-β1 has been shown to protect against autoimmune diseases. For example, The cellular composition of islet grafts in mice from the different treatment groups was compared at 8-12
transgenic expression of TGF-β1 in islet β-cells pro- Blood glucose values in individual NOD mice before (day 0) and up to 31 days after renal subcapsular transplantation of 500 syngeneic islets that were not transfected (0) and transfected with an adenoviral DNA expression vector encoding porcine latent TGF-β1 (Ad TGF-β1) or the adenoviral vector alone (control Ad vector). All islet grafts initially corrected diabetes (blood glucose <7 mmol/L) in the NOD mice; however, diabetes recurred (blood glucose >12 mmol/L) from day 6 to 11 in mice with nontransfected islet grafts (n = 7), day 6 to 14 in mice with control Ad vector-transfected grafts (n = 7), and day 13 to 31 in mice with Ad TGF-β1-transfected grafts (n = 8). Figure 3 . Median graft survival (days of normoglycemia after islet transplantation) was 9 days for nontransfected islet grafts, 7 days for control Ad vector-transfected grafts, and 22 days for Ad TGF-β1-transfected grafts (p = 0.001 vs. control Ad vector-transfected islet grafts).
tected NOD mice from developing diabetes, and the pro-TGF-β1 is observed after treatment with acid or proteases. Therefore, TGF-β1 may become biologically ac-tective effect was related to diverting immune responses to islet antigen from a Th1 towards a Th2 phenotype tive only at inflammatory sites, such as the insulitis lesion, through the action of macrophages, low pH, or (14). In other studies, transgenic expression of TGF-β1 in pancreatic α-cells protected NOD mice from develop-other factors (30) . In this study, TGF-β1 action was localized to the islet graft because we did not detect any ing diabetes, and the protective action of TGF-β1 was related to blocking the cytotoxic effects of diabetogenic increase in circulating blood levels of latent or active TGF-β1 (data not shown). effector lymphocytes (20). Also, intramuscular administration of a naked plasmid DNA expression vector en-Islets that overexpressed TGF-β1 after Ad TGF-β1 transfection were protected from autoimmune destruc-coding murine TGF-β1 protected NOD mice from insulitis and diabetes in models of cyclophosphamide-tion for ≥2 weeks after transplantation into diabetic NOD mice, whereas control Ad vector-transfected and accelerated and natural course disease (22) .
In this study, we demonstrate for the first time that nontransfected islets were all sufficiently damaged that diabetes recurred within 2 weeks after transplantation. local overexpression of the TGF-β1 in islets protected β-cells in islet grafts from a recurrent autoimmune re-Although diabetes recurrence was significantly delayed, it was not prevented beyond 30 days in mice that re-sponse elicited by transplanting syngeneic islets into diabetic NOD mice. The Ad TGF-β1 expression vector we ceived islet grafts transfected with TGF-β1. This may have been due to loss of continued expression of the used proved to be very effective in increasing the numbers of islet cells that expressed TGF-β1 protein, both TGF-β1 gene and/or the generation of an immunogenic response to adenoviral proteins. These limitations of ad-total islet cells (89% vs. 12% for control Ad vector transfections) and islet β-cells (60% vs. 12% for control enoviral vectors for gene delivery may be overcome by using other DNA delivery vectors, such as lentiviral Ad vector transfections). Also, TGF-β1 secretion from Ad TGF-β1-transfected islet cells was increased seven- (6, 9) and baculoviral (18) vectors. By examining islet grafts at 8-12 days after trans-fold over 48 h in vitro. The molecular form of TGF-β1 secreted was the latent (inactive) form of TGF-β1 that plantation, we found that twice as many cells in the grafts transfected with Ad TGF-β1 expressed TGF-β1 was encoded in the adenoviral DNA expression vector used to transfect the islet cells. Cells normally secrete compared with grafts transfected with Ad control vector. Importantly, apoptosis of β-cells was significantly de-TGF-β1 as a latent complex formed by noncovalent interaction of the mature biologically active TGF-β1 ho-creased in islet grafts that overexpressed TGF-β1 and twice as many insulin-producing β-cells survived. In modimer with a dimer of the glycosylated and phosphorylated NH2-terminal precursor segments. Activation of contrast, apoptosis of leukocytes was significantly increased in islet grafts that overexpressed TGF-β1 and this latent complex into the biologically active form of islet graft-infiltrating leukocytes were decreased to one treatment of islets with TGF-β1 prior to transplantation prolonged rat islet xenograft survival (3), and treatment fifth the number seen in the islet grafts transfected with control Ad vector. Therefore, TGF-β1 may have pro-of recipient mice with TGF-β1 also inhibited islet allograft rejection (10) . tected islet β-cells by inducing apoptosis of islet-infiltrating leukocytes and/or by acting on β-cells and block-
In conclusion, the present study demonstrates that local production of TGF-β1 by islets transfected with an ing apoptosis induced by islet-infiltrating leukocytes.
TGF-β1 has been reported to promote as well as to adenoviral gene vector encoding latent TGF-β1 protects syngeneic islets from autoimmune destruction after prevent apoptosis, depending on the target cell. For example, TGF-β1 can induce apoptosis in T cells (2), eo-transplantation into diabetic NOD mice. The protective effects of TGF-β1 involved apoptosis of graft-infiltrat-sinophils (1), and hepatocytes (21). On the other hand, TGF-β1 has been reported to prevent destruction of a ing leukocytes and prevention of β-cell apoptosis. It remains to be determined whether TGF-β1 gene therapy rat β-cell line (RINm5F) induced by a combination of proinflammatory cytokines: IL-1β, tumor necrosis factor can protect against the combined allo-and autoimmune responses elicited by transplantation of allogeneic islets (TNF)-α, and interferon (IFN)-γ (19) . In addition, pretreatment of rat islet cells with TGF-β1 protected the into diabetic NOD mice. islet cells from destruction by lymphocytes from acutely ACKNOWLEDGMENTS: This work was supported by a grant diabetic Biobreeding/Worcester (BB/Wor) rats and by from the Canadian Institutes of Health Research (FRN 11444) and a partnership program grant from the Juvenile Diabetes the cytokines TNF-α and IFN-γ (15) . In other studies, Figure 6 . Immunohistochemial analysis of cells in NOD mouse islet grafts at 8-12 days after transplantation into diabetic NOD mice. TGF-β1-expressing cells (TGF-β1 + ) and β-cells (insulin + ) were significantly increased and leukocytes (CD45 + ) were significantly decreased in islet grafts transfected with an adenoviral DNA expression vector encoding porcine latent TGF-β1 (Ad TGF-β1). Mean values ± SE are shown for five grafts. *p < 0.01 vs. control Ad vector. Figure 7 . Immunohistochemical analysis of cells undergoing apoptosis in NOD mouse islet grafts at 8-12 days after transplantation into diabetic NOD mice. Apoptotic β-cells (TUNEL + insulin + ) were significantly decreased whereas apoptotic leukocytes (TUNEL + CD45 + ) were significantly increased in islet grafts transfected with an adenoviral DNA expression vector encoding porcine latent TGF-β1 (Ad TGF-β1). Mean values ± SE are shown for five grafts. *p < 0.01 vs. control Ad vector.
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